Hai Lin

1.6k total citations
41 papers, 1.1k citations indexed

About

Hai Lin is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Hai Lin has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 23 papers in Hematology and 7 papers in Genetics. Recurrent topics in Hai Lin's work include Acute Myeloid Leukemia Research (21 papers), Cell death mechanisms and regulation (11 papers) and Histone Deacetylase Inhibitors Research (11 papers). Hai Lin is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Cell death mechanisms and regulation (11 papers) and Histone Deacetylase Inhibitors Research (11 papers). Hai Lin collaborates with scholars based in China, United States and Saint Kitts and Nevis. Hai Lin's co-authors include Yubin Ge, Holly Edwards, Jeffrey W. Taub, Guan Wang, Jianyun Zhao, Jun Ma, Xiaojia Niu, Yongwei Su, Daniel A Luedtke and Chengzhi Xie and has published in prestigious journals such as Nature Communications, Blood and Scientific Reports.

In The Last Decade

Hai Lin

38 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hai Lin China 19 838 621 207 158 86 41 1.1k
Obdulio Piloto United States 12 516 0.6× 588 0.9× 145 0.7× 257 1.6× 95 1.1× 21 940
Aaron Nguyen United States 12 695 0.8× 421 0.7× 207 1.0× 79 0.5× 80 0.9× 21 966
Terry J. Gaymes United Kingdom 13 585 0.7× 280 0.5× 265 1.3× 105 0.7× 80 0.9× 24 800
Ruriko Tanaka Japan 14 357 0.4× 346 0.6× 159 0.8× 199 1.3× 103 1.2× 23 727
Melissa Ooi Singapore 15 589 0.7× 409 0.7× 280 1.4× 89 0.6× 73 0.8× 75 848
Pablo Baquero Spain 12 620 0.7× 316 0.5× 188 0.9× 152 1.0× 52 0.6× 17 959
Joyce James United States 9 490 0.6× 821 1.3× 123 0.6× 378 2.4× 52 0.6× 19 1.1k
P. Oriol France 8 545 0.7× 324 0.5× 231 1.1× 87 0.6× 92 1.1× 21 781
Jake Delmore United States 17 614 0.7× 332 0.5× 367 1.8× 43 0.3× 86 1.0× 32 967
Eleni D. Lagadinou Greece 7 764 0.9× 550 0.9× 222 1.1× 108 0.7× 131 1.5× 11 1.1k

Countries citing papers authored by Hai Lin

Since Specialization
Citations

This map shows the geographic impact of Hai Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hai Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hai Lin more than expected).

Fields of papers citing papers by Hai Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hai Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hai Lin. The network helps show where Hai Lin may publish in the future.

Co-authorship network of co-authors of Hai Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Hai Lin. A scholar is included among the top collaborators of Hai Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hai Lin. Hai Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Shuang, Xinyu Li, Hai Lin, et al.. (2022). Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine. 26(9). 2646–2657. 16 indexed citations
2.
Liu, Shuang, Yongwei Su, Holly Edwards, et al.. (2022). c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. APOPTOSIS. 27(11-12). 913–928. 16 indexed citations
3.
Su, Long, Yehui Tan, Hai Lin, et al.. (2022). Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia. Annals of Hematology. 102(2). 337–347.
4.
Zhang, Xiaoling, et al.. (2022). The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy. Frontiers in Oncology. 12. 1015792–1015792. 4 indexed citations
5.
Ma, Jun, Tristan Knight, Yongwei Su, et al.. (2021). The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer Journal. 11(6). 111–111. 27 indexed citations
6.
Liu, Fangbing, Yongwei Su, Jing Lv, et al.. (2021). Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. Experimental Hematology. 105. 39–49. 13 indexed citations
7.
Luedtke, Daniel A, Yongwei Su, Jun Ma, et al.. (2020). Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduction and Targeted Therapy. 5(1). 17–17. 50 indexed citations
8.
Zhu, Ruili, Cong-En Zhang, Rui Liu, et al.. (2020). Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition. Journal of Ethnopharmacology. 281. 113305–113305. 18 indexed citations
9.
Ma, Jun, Tristan Knight, Holly Edwards, et al.. (2019). Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clinical Cancer Research. 25(22). 6815–6826. 117 indexed citations
10.
Wang, Tingting, Fangbing Liu, Tristan Knight, et al.. (2019). Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia. Signal Transduction and Targeted Therapy. 4(1). 44–44. 4 indexed citations
11.
Su, Long, Sujun Gao, Yehui Tan, et al.. (2019). CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations. Annals of Hematology. 98(7). 1641–1646. 22 indexed citations
12.
Luedtke, Daniel A, Yongwei Su, Shuang Liu, et al.. (2018). Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1. Journal of Cellular and Molecular Medicine. 22(12). 6099–6111. 46 indexed citations
13.
Pitre, Aaron, Yubin Ge, Wenwei Lin, et al.. (2017). An unexpected protein interaction promotes drug resistance in leukemia. Nature Communications. 8(1). 1547–1547. 20 indexed citations
14.
15.
Su, Yongwei, Xinyu Li, Jun Ma, et al.. (2017). Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochemical Pharmacology. 148. 13–26. 39 indexed citations
16.
Luedtke, Daniel A, Xiaojia Niu, Yihang Pan, et al.. (2017). Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy. 2(1). 17012–17012. 101 indexed citations
17.
Niu, Xiaojia, Jianyun Zhao, Jun Ma, et al.. (2016). Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clinical Cancer Research. 22(17). 4440–4451. 181 indexed citations
18.
Lin, Hai, et al.. (2014). Eosinophilic Fasciitis following Allogeneic Bone Marrow Transplantation in a Patient with Acute Myeloid Leukaemia. Acta Dermato Venereologica. 94(2). 221–222. 5 indexed citations
19.
Zhou, Liang, Yuesheng Zhang, Maciej Kmieciak, et al.. (2014). A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia. 29(4). 807–818. 63 indexed citations
20.
Yang, Yan, et al.. (2013). Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion. Experimental and Therapeutic Medicine. 6(3). 803–807. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Obdulio Piloto Breakdown of academic impact, for papers by Aaron Nguyen Breakdown of academic impact, for papers by Terry J. Gaymes Breakdown of academic impact, for papers by Ruriko Tanaka Breakdown of academic impact, for papers by Melissa Ooi Breakdown of academic impact, for papers by Pablo Baquero Breakdown of academic impact, for papers by Joyce James Breakdown of academic impact, for papers by P. Oriol Breakdown of academic impact, for papers by Jake Delmore Breakdown of academic impact, for papers by Eleni D. Lagadinou
Rankless by CCL
2026